TaperMD uses content from CredibleMeds® to create a flag for medications with potential cardiac risk.
The CredibleMeds® content contains drugs categorized by their potential to cause QT prolongation and/or torsades de pointes (TdP), a lethal arrhythmia.
General guidelines from CredibleMeds® include:
- If possible, do not prescribe QT-prolonging drugs to anyone with a QT > 440ms (female) or 420ms (male).
- Do not allow the QT to exceed 500ms during titration with these drugs.
- Be aware of drug interactions that could result in greater exposure to the QT-prolonging drugs by blocking their metabolism or delaying clearance.
- Electrolyte abnormalities, age, and female sex increase the risk.
Visit CredibleMeds® for more detailed information on the issues they cover as well as summaries derived from the FDA drug monographs of QT/TDP issues.
Categories of risk assigned:
- Drugs with a known risk of TdP.
- Drugs with a possible risk of TdP.
- Drugs with a conditional risk of TdP – i.e., can cause TdP under certain conditions.
- Drugs to be avoided by congenital Long QT patients.
The cumulative burden is important – you can also click on an individual drug to see if the full FDA label.
Reference(s): Woosley RL, Heise CW , Gallo T, Tate J, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs List, [March 4, 2020], AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755